Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N

in response to

Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N

narmac

posted on Mar 01, 2024 11:55AM

narmac - I have no problem with any of the reasons you are unhappy with this unlisted reporting company.

The challenge is if you know all of this and are still ticked off yet have an exit, why are you continuing let this pig drag you down?

Don't all of us have an obligation to put our own mental heath a little higher on the scale?

tada

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply